LLY
$LLY
Eli Lilly and Company
Pharmaceutical heavyweight known for weight-loss drugs Mounjaro and Zepbound.
HealthcareSubscribers
16
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
This week's analysis
LLY: GLP-1 Growth Powers Upside (LLY)
Eli Lilly reported a blockbuster Q2 FY26 with Zepbound and Mounjaro driving revenue and guidance upgrades. Strong fundamentals and analyst targets show upside, but high multiples and pricing scrutiny create measurable risks.
Aug 15, 2026